News

Oregon Sen. Ron Wyden is in his fifth decade in Congress and showing no inclination to step aside even as pressure builds on ...
The company reported a net loss attributable to common stockholders of $5.7 million, or $1.99 per share, for the three months ended June 30, 2025, compared to a net loss attributable to common ...
With the field of HER2-positive breast cancer evolving rapidly, how will practice change in the clinic after the recent ...
MATTERHORN supports the global adoption of perioperative durvalumab plus FLOT as a new standard for patients with localized gastric and gastroesophageal junction adenocarcinoma,” said Yelena Y.
Rocket, a therapy horse, visited the Pasco County Fire Rescue on Thursday and brought joy to the first responders.
Relay Therapeutics beat analyst estimates for both GAAP revenue and earnings per share in Q2 2025. The company reported continued clinical advancement of its lead asset RLY-2608, with new positive ...
Revenue: Revenue was $0.7 million for the second quarter of 2025, as compared to $0 for the second quarter of 2024.
NDA for icotrokinra for the treatment of adults and adolescents 12 years of age and older with moderate to severe plaque ...
More and more providers are beginning to incorporate the new Practical Geriatric Assessment into their practices.
Building on bispecific antibodies, four of which have been approved by the FDA to treat relapsed/refractory multiple myeloma, ...